NCT05694923View on ClinicalTrials.gov

Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

April 1, 2024

Conditions
Fatty Liver Disease
Interventions
DRUG

Empagliflozin 10 MG

non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg

Trial Locations (2)

71515

Faculty of Medicine, Asyut

Unknown

Bahaa Osman, Asyut

All Listed Sponsors
lead

Assiut University

OTHER